Brief: Pharming Group Expects 2024 Total Revenue Of $280 Mln - $295 Mln

Pharming

14/03/2024 06:07

March 14 (Reuters) - Pharming Group NV  PHAR.AS :
    * PHARMING GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2023
FINANCIAL RESULTS
    * 2024 TOTAL REVENUE GUIDANCE OF US$280 MILLION - US$295
MILLION
(14% - 20% GROWTH)
    * FULL YEAR 2023 TOTAL REVENUES INCREASED BY 19% TO US$245.3
MILLION
    * OVERALL CASH AND MARKETABLE SECURITIES INCREASED TO
US$215.0
MILLION AT END OF 2023 FROM US$208.7 MILLION AT END OF 2022
    * OUTLOOK 2024: CONTINUED FOCUS ON POTENTIAL ACQUISITIONS
AND
IN-LICENSING OF CLINICAL STAGE OPPORTUNITIES IN RARE DISEASES.
FINANCING, IF REQUIRED, WOULD COME VIA A COMBINATION OF OUR
STRONG BALANCE SHEET AND ACCESS TO CAPITAL MARKETS
    * OUTLOOK 2024: NO MATERIAL CASH BURN IS EXPECTED PRIOR TO
IMPACT
OF POTENTIAL ACQUISITION OR IN-LICENSING TRANSACTIONS

Source text for Eikon:  ID:nGNX3p0z9L 
Further company coverage:  PHAR.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))